Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.

PloS one - 1 Jan 2013

Boursault Lucile, Haddad Véronique, Vergier Béatrice, Cappellen David, Verdon Severine, Bellocq Jean-Pierre, Jouary Thomas, Merlio Jean-Philippe

Abstract excerpt

BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melanoma and BRAF(V600) mutations. In order to evaluate BRAF tumor heterogeneity between primary and metastatic site, we have evaluated the performance of immunohistochemistry (IHC) with an anti-BRAF(V60...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression
Share to Immunohistochemistry
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Nucleic Acid Denaturation

Share to Proto-Oncogene Proteins B-raf

Share to Sensitivity and Specificity

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 23976959
DOI: 10.1371/journal.pone.0070826
PMCID: PMC3748080

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23976959-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.PMID 23976959Read ↗

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.Semantic proximity Read ↗

Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors.Semantic proximity Read ↗

BRAF Heterogeneity in Melanoma.Semantic proximity Read ↗

Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.Semantic proximity Read ↗

BRAF V600E Mutation in Malignant Melanoma-A Romanian Research Experience.Semantic proximity Read ↗

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutationsSemantic proximity Read ↗

Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.Semantic proximity Read ↗

Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.Semantic proximity Read ↗

Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.Semantic proximity Read ↗

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.Semantic proximity Read ↗

Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.Semantic proximity Read ↗

BRAFV600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.